Six years since the FDA blessed Sanofi and Regeneron’s Dupixent as the first biologic to treat chronic rhinosinusitis with nasal polyps (CRSwNP), a second biologic therapy has broken through with a ...
AstraZeneca (AZN) and Amgen’s (AMGN) Tezspire has been recommended for approval in the European Union, EU, for the treatment of adult patients with chronic rhinosinusitis with nasal polyps, CRSwNP.
Sanofi and Regeneron’s Dupixent appears set up for a key FDA approval this summer for chronic obstructive pulmonary disorder (COPD). But a second biologic treatment could be on its heels in the ...
Amgen Inc. (NASDAQ:AMGN) is one of the Most Undervalued Growth Stocks to Buy According to Hedge Funds. On September 22, Amgen Inc.’s (NASDAQ:AMGN) and AstraZeneca’s Tezspire received a positive ...
Hosted on MSN
Amgen, AstraZeneca announce FDA approval of Tezspire
Amgen (AMGN) and AstraZeneca (AZN) announced that the U.S. FDA approved Tezspire for the add-on maintenance treatment of inadequately controlled chronic rhinosinusitis with nasal polyps in adult and ...
THOUSAND OAKS, Calif., April 16, 2024 /PRNewswire/ -- Amgen (AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE ® (tezepelumab-ekko) in chronic obstructive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results